Spyre Therapeutics, Inc. SYRE Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s business segments — net loss?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — net loss of -$69.01M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — net loss changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — net loss decreased by 54.1% year-over-year, from -$44.77M to -$69.01M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — net loss has grown at a 22.8% compound annual growth rate (CAGR), from -$83.82M to -$155.2M.
- What does business segments — net loss mean?
- The total loss generated by this business segment after all expenses.
- How do you interpret business segments — net loss?
- A narrowing loss suggests improved operational efficiency or a transition toward commercialization, while a widening loss reflects increased investment in development.
- How does business segments — net loss compare across companies?
- Standard metric for pre-revenue or clinical-stage biotech; compared against cash runway to assess financial health.